Article
Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.
Molecular oncology - 1 Jul 2026
Dienstmann Rodrigo, García-Galea Eduardo, O'Farrell Alice, Kinsella Zak, Meylan Maxime, Petitprez Florent, Arijs Ingrid, Venken Tom, Ps Hari, Lärkeryd Adrian, Miller Ian, Selves Janick, Meindl-Beinker Nadja, Ruiz-Pace Fiorella, Élez Elena, Comas-Navarro Raquel, Lincoln Frank, Fey Dirk, Nyamundanda Gift, Nolan Aoife, Lewin Joern, Perez-Lopez Raquel, Briody Jonathan, Bennett Kathleen, Kolch Walter, Matallanas David, Kel Alexander, Arenas Enrique, Arribas Joaquín, Ghesquière Bart, Tabernero Josep, Meilleroux Julie, McNamara Deborah, McDermott Ray, Lim Marvin, O'Reilly Mary, Bird Brian, Stack Lisa, Moloney Lucia, Morris Patrick, Egan Keith, Milewski Maciej, Scheuer Lars, Behringer Joachim, Bolz Georg, Salazar Ramon, Santos Cristina, Ruiz Andrea, Casey Orla, Murphy Verena, Ebert Matthias, Trusolino Livio, Lambrechts Diether, Sadanandam Anguraj, Sautès-Fridman Catherine, Prehn Jochen, Nuciforo Paolo, Fieschi Jacques, Monville Florence, O'Connor Darran, Fridman Wolf, Byrne Annette
Abstract excerpt
To explore the immune microenvironment of RAS-mutated (RASmt) microsatellite stable (MSS) colon cancer (CC), we retrospectively performed whole exome sequencing, RNA sequencing, and robust digital pathology analyses and studied immune markers in a cohort of 161 patients treated with standard-of-care therapies with early stage disease (both fresh frozen and formalin-fixed paraffin-embedded [FFPE] samples) or 121...
Read the complete abstract on PubMed